What tools does a university administration have at its disposal to shut up critics on its own faculty? The University of Minnesota wants to know.
The university's administration is exploring this question because its own Carl Elliott won't shut up about the Markingson case. Elliott, a professor in the Center for Bioethics, just keeps talking about what went wrong at his medical school in a 2003 industry-sponsored drug trial in which research subject Dan Markingson killed himself. Since publication of a muckraking article on the subject in Mother Jones, Elliott has criticized the FDA's response to the case and led a group of faculty in asking the University Trustees to look into the case.
Like many others who continue to follow this story, Elliott is drawn to this case by issues of justice both local and global. Locally, he seeks accountability for what happened to Dan Markingson and to his mother, who tried repeatedly before Dan's gruesome suicide to convince involved clinicians that study participation went against Dan's best interests.
But Elliott also sees in this story the impetus for...
By Antonio Regalado, MIT Technology Review | 03.20.2024
Aggregated News
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.